Meropenem Steriscience

Meropenem, the active ingredient in Meropenem Steriscience, is a carbapenem antibiotic presented as an intravenous solution for IV use. It treats severe bacterial infections such as complicated intra‑abdominal, urinary tract, skin and soft‑tissue infections, as well as pneumonia, meningitis, septicemia, and febrile neutropenia in hospitalized patients.

GNH USA supplies Meropenem Steriscience as a licensed, GMP‑aligned, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance, to meet the needs of critical care environments.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious bacterial infections across several organ systems. - Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure in patients with perforated or postoperative abdominal infections. - Complicated urinary tract infections: eliminates resistant Gram‑negative pathogens causing pyelonephritis and cystitis. - Complicated skin and soft‑tissue infections: achieves resolution of cellulitis, abscesses, and necrotizing infections. - Nosocomial and community‑acquired pneumonia: delivers rapid bacterial clearance in hospital‑acquired and community‑origin lung infections. - Meningitis and septicemia: penetrates the cerebrospinal fluid and bloodstream to treat life‑threatening systemic infections.

Adverse reactions to Meropenem may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset that may resolve without treatment and may affect appetite. - Diarrhea: often self‑limiting watery stools, occasionally requiring rehydration and can cause dehydration. - Headache: transient cranial discomfort, usually responsive to analgesics and occasionally accompanied by photophobia. - Rash: mild erythematous skin eruption without systemic involvement and may include pruritus. - Elevated liver enzymes: mild, reversible increase in transaminases and usually normalizes after therapy.

Serious or Rare Side Effects: - Seizures: risk increases in patients with renal impairment or pre‑existing CNS disorders, especially with high plasma concentrations. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome requiring immediate medical care and may progress rapidly. - Clostridioides difficile colitis: potentially life‑threatening diarrhea associated with antibiotic‑associated flora disruption and requiring isolation precautions. - Thrombocytopenia: marked reduction in platelet count that may lead to bleeding and may require platelet transfusion. - Renal toxicity: acute kidney injury observed in predisposed individuals, necessitating monitoring and may necessitate dose adjustment.

When using Meropenem, clinicians should observe several precautionary measures to minimize risks. - Renal function assessment: evaluate baseline creatinine clearance and adjust dose in impairment. - Allergy history: confirm no known hypersensitivity to β‑lactam antibiotics or carbapenems. - Concomitant nephrotoxins: avoid or closely monitor use with other kidney‑toxic drugs. - CNS disorders: use caution in patients with seizure history or central nervous system disease. - Monitoring for superinfection: watch for signs of Clostridioides difficile infection during therapy. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: concomitant use can reduce serum valproate levels, risking seizure breakthrough. - Probenecid: may decrease renal clearance of Meropenem, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxic potential requires renal function monitoring. - Loop diuretics: may enhance nephrotoxicity, necessitate dose adjustment. - Anticoagulants (warfarin): possible alteration of INR, monitor coagulation parameters. - Oral contraceptives: may have reduced effectiveness, advise backup contraception. - Phenytoin: may increase clearance of Meropenem, monitor therapeutic response.